Drug Patents owned by Global Blood Theraps

1. Drug name - OXBRYTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10034879 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Dec, 2032

(10 years from now)

US9018210 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Dec, 2032

(10 years from now)

US10806733 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Dec, 2032

(10 years from now)

US9447071 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(12 years from now)

CN105431147A GLOBAL BLOOD THERAPS 2-Hydroxy--6-((2-(1-Isopropyl--1H-Pyrazol--5-Yl) Pyridine--3-Yl) Methoxy) Benzaldehyde And Free Alkali Is Crystalline Polymorph
Apr, 2022

(5 months ago)

CN107176953A GLOBAL BLOOD THERAPS Substituted Benzaldehyde Compound And Its Method For Increasing Tissue Oxygenation
Dec, 2032

(10 years from now)

CN104135859A GLOBAL BLOOD THERAPS Substituted Benzaldehyde Compound And Its Method For Increasing Tissue Oxygenation
Dec, 2032

(10 years from now)

CN104135859B GLOBAL BLOOD THERAPS Substituted Benzaldehyde Compound And Its Method For Increasing Tissue Oxygenation
Dec, 2032

(10 years from now)

CN107176953B GLOBAL BLOOD THERAPS Substituted Benzaldehyde Compound And Method For Increasing Tissue Oxygenation
Dec, 2032

(10 years from now)

IN322527B GLOBAL BLOOD THERAPS Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation
Dec, 2032

(10 years from now)

EP3141542B1 GLOBAL BLOOD THERAPS Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation
Dec, 2032

(10 years from now)

EP3141542A1 GLOBAL BLOOD THERAPS Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation
Dec, 2032

(10 years from now)

EP2797416A4 GLOBAL BLOOD THERAPS Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation
Dec, 2032

(10 years from now)

EP2797416A1 GLOBAL BLOOD THERAPS Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation
Dec, 2032

(10 years from now)

EP2797416B1 GLOBAL BLOOD THERAPS Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation
Dec, 2032

(10 years from now)

EP3102208A1 GLOBAL BLOOD THERAPS Crystalline Polymorph Of The Free Base Of 2-Hydroxy-6-((2-(1-Isopropyl-1H-Pyrazol-5-Yl)Pyridin-3-Yl)Methoxy)Benzaldehyde
Feb, 2035

(12 years from now)

EP3102208A4 GLOBAL BLOOD THERAPS Crystalline Polymorphs Of The Free Base Of 2-Hydroxy-6-((2-(1-Isopropyl-1H-Pyrazol-5-Yl)Pyridin-3-Yl)Methoxy)Benzaldehyde
Feb, 2035

(12 years from now)

EP3102208B1 GLOBAL BLOOD THERAPS Crystalline Polymorph Of The Free Base Of 2-Hydroxy-6-((2-(1-Isopropyl-1H-Pyrazol-5-Yl)Pyridin-3-Yl)Methoxy)Benzaldehyde
Feb, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10017491 GLOBAL BLOOD THERAPS Compounds and uses thereof for the modulation of hemoglobin Dec, 2032

(10 years from now)

US9248199 GLOBAL BLOOD THERAPS 1:1 adducts of sickle hemoglobin Jan, 2034

(11 years from now)

US10722502 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde Feb, 2035

(12 years from now)

US11020382 GLOBAL BLOOD THERAPS Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde Dec, 2036

(14 years from now)

US10493035 GLOBAL BLOOD THERAPS Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde Oct, 2037

(15 years from now)

Drugs and Companies using VOXELOTOR ingredient

Treatment: Treatment of sickle cell disease by administering voxelotor, as recited in claim 1; treatment of sickle cell disease by administering voxelotor, as recited in claim 2; Treating sickle cell disease by administering 1500 mg of voxelotor orally once daily; increasing hemoglobin to treat sickle cell disease by administering 1500 mg of voxelotor orally once daily

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
500MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.